SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q1 2022 vs. Q4 2021
How the institutions holding SAB Biotherapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 34 | 27 | −7 |
| Shares | 3.10M | 1.79M | −1.31M (−42.2%) |
| Value | $25.4M | $6.71M | −$18.7M (−73.6%) |
New holders (2)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Creative Planning | 46,528 | $175.0K | 0.00% |
| Money Concepts Capital Corp | 250 | $1.00K | 0.00% |
Sold out (9)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| First PREMIER Bank | 832,555 | $6.50M |
| Radcliffe Capital Management, L.P. | 546,658 | $5.52M |
| Citadel Advisors LLC | 24,230 | $189.0K |
| Virtu Financial LLC | 15,379 | $120.0K |
| Susquehanna International Group, LLP | 15,117 | $118.0K |
| Cubist Systematic Strategies, LLC | 12,899 | $101.0K |
| Nadler Financial Group, Inc. | 11,000 | $86.0K |
| Charles Schwab Investment Management Inc | 10,000 | $79.0K |
| Marshall Wace, LLP | 498 | $3.00K |